Login to Your Account

Clinic Roundup

Wednesday, December 14, 2011
• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., commenced its first Phase Ia safety study for its investigational drug, CPP-115, a GABA aminotransferase inhibitor being developed under a licensing agreement with Northwestern University. The randomized, double-blind, single-ascending dose study will evaluate the vigabatrin analogue in six cohorts of eight healthy volunteers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription